跳转到内容

帕曲妥单抗

编辑链接
维基百科，自由的百科全书
帕曲妥单抗
单克隆抗体
种类完整抗体
目标HER3（英语：ERBB3）
临床资料
ATC码
  • 未分配
识别信息
CAS号1262787-83-6
ChemSpider
  • none
UNII
KEGG

帕曲妥单抗（INN：Patritumab）是一种人单克隆抗体，设计用于治疗非小细胞肺癌（英语：Non-small-cell lung cancer）。它充当免疫调节剂。[1][2]

临床试验

[编辑]

它正在进行针对头颈部鳞状细胞癌的二期临床试验。[3]

它将被纳入I-SPY 2乳腺癌试验的新组中。[4]

参考资料

[编辑]
  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4) [2024-01-24]. （原始内容存档 (PDF)于2016-03-04）. 
  2. ^ Horinouchi H. The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy. December 2016, 16 (12): 1549–1555. PMID 27744717. S2CID 4035336. doi:10.1080/14712598.2016.1249846. 
  3. ^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
  4. ^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. October 2016 [2024-01-24]. （原始内容存档于2024-01-24）. 
检索自“https://zh.wikipedia.org/w/index.php?title=帕曲妥单抗&oldid=83907398”